Business and Finance

Analysis from Prime Therapeutics points to severe cost hurdles for biosimilars developed and marketed in the US

Manufacturers will need to refine their interactions with healthcare providers and produce better outcomes research and adherence programs to compete

Mapi Group casts itself as a leading 'health research and commercialization' player

So long WAG, hello to WBA as pharma manufacturers look at a consolidating buyer landscape

Express Scripts touts a 'fundamental change' in drug pricing; others would call it negotiating a discount

When state and federal governments are involved, prices and reimbursements have both regulatory and financial consequences

A big jump in 2012-2013 venture funding will fuel growth; BMS' new facility

Company is part of limited distribution for a Lundbeck neurologic treatment

Payer trends dominate near-term outlook

Efforts to align drug wholesaling business with manufacturer services

Largest independent specialty pharmacy rides specialty-pharma wave

Vendor-managed system inventories and protects specialty pharmaceuticals in healthcare settings

Pharmaceutical Commerce sat down with Mr. Mortazavi recently; here's what he had to say.

Absence of agreed-on FDA guidance keeps biosimilars off the US market even as their use grows abroad

Battlefield over drug pricing

Blackstone Group-owned CDMO nets over $800 million

Outsourced contract-administration provider highlights growth in invoicing and financial stewardship burdens

Acquisition will add C3i's multilingual service-desk support to Telerx's call centers

Pharmaceutical Commerce sat down with Angela Miccoli, president, Cegedim Relationship Management NA since 2009. Here's what she had to say.

Annual IMS Institute survey finds generics level at 86%

2014 EMD Serono Specialty Digest: managing adherence programs are a sought-after service

Annual survey tracks rapid evolution in a critical pharma market